← IRulya Therapeutics Inc. (IRLA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IRulya Therapeutics Inc. (IRLA)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · LAM-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Apilimod Dimesylate Capsule | Phase 2 | COVID-19 Disease |
| LAM-001 | Phase 2 | Pulmonary Hypertension Due to Lung Diseases and Hypoxia |
| LAM-002A | Phase 2 | Amyotrophic Lateral Sclerosis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IRLA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.